Researchers working with ultrasound contrast developer Sonus Pharmaceuticalspresented data about a new contrast agent, QW7437, at last week'sAmerican Heart Association meeting in New Orleans. The Bothell,WA, company said QW7437 is a third-generation
Researchers working with ultrasound contrast developer Sonus Pharmaceuticalspresented data about a new contrast agent, QW7437, at last week'sAmerican Heart Association meeting in New Orleans. The Bothell,WA, company said QW7437 is a third-generation agent that studiesindicate may be capable of producing myocardial perfusion at lowdoses with no hemodynamic effects.
Researchers from the University of California at San Diegoworking with the new agent presented data from animal studiesfor the first time at a major medical conference. QW7437 is aphase-shift emulsion that is stabilized with a negative-chargedsurfactant.
Investigators at the AHA meeting also presented data on thecompany's lead EchoGen agent, including an animal study by DukeUniversity researchers in which EchoGen was used to make 3-D measurementsof the left ventricle muscle mass in a single cardiac cycle.
GE HealthCare Debuts AI-Powered Cardiac CT Device at ACC Conference
April 1st 2025Featuring enhanced low-dose image quality with motion-free images, the Revolution Vibe CT system reportedly facilitates improved diagnostic clarity for patients with conditions ranging from in-stent restenosis to atrial fibrillation.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.